Japan · Delayed Price · Currency is JPY FunPep Company Company Description
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices in Japan and internationally.
The company develops SR-0379, a functional peptide which is in Phase III clinical trial for the treatment of skin ulcer; FPP003, an antibody-inducing peptide which is in Phase II clinical trial for the treatment of psoriasis and ankylosing spondylitis; FPP004X, an antibody-inducing peptide which is in Phase I clinical trial for the treatment of pollinosis; and FPP005, an antibody-inducing peptide which is in pre-clinical trial stage for the treatment of psoriasis.
It is also involved in the development of Curepeptin, an antimicrobial peptide that disrupts bacterial cell membranes.
The company was incorporated in 2013 and is headquartered in Ibaraki, Japan.
| Country | Japan |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Toshimi Miyoshi |
Contact Details
Address: 7-15, Saito Asagi 7-chome Ibaraki Japan | |
| Phone | 81 3 5315 4200 |
| Website | funpep.co.jp |
Stock Details
| Ticker Symbol | 4881 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3802640007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Toshimi Miyoshi | Chief Executive Officer |
| Taketoshi Hayashi | Chief Financial Officer |